Literature DB >> 18799178

An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.

Carla Cohen1, Mario Forzan, Brian Sproat, Ralph Pantophlet, Ian McGowan, Dennis Burton, William James.   

Abstract

We have previously isolated nucleic acid ligands (aptamers) that bind the surface envelope glycoprotein, gp120, of HIV-1, and neutralize infection of diverse sub-types of virus. Our earlier studies have identified the overall structure of one of these aptamers, B40, and have indicated that it binds to gp120 in a manner that competes with that of the HIV-1 coreceptor, CCR5, and select "CD4i" antibodies with epitopes overlapping this region. Here, we sought to map the B40 binding site on gp120 more precisely by analysing its interaction with a panel of alanine substitution mutants of gp120. Furthermore, we tested our hypothesis concerning the structure of the 40 nucleotide functional core of the aptamer by the solid-phase synthesis of truncated and chemically modified derivatives. The results confirm our structural predictions and demonstrate that aptamer B40 neutralizes a diverse range of HIV-1 isolates as a result of binding to relatively conserved residues on gp120 at the heart of the CCR5-binding site. These structural insights may provide the basis for the development of potential anti-viral agents with high specificity and robustness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799178      PMCID: PMC4380131          DOI: 10.1016/j.virol.2008.08.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

1.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Authors:  Ramalakshmi Darbha; Sanjay Phogat; Aran F Labrijn; Yuuei Shu; Yijun Gu; Michelle Andrykovitch; Mei-Yun Zhang; Ralph Pantophlet; Loic Martin; Claudio Vita; Dennis R Burton; Dimiter S Dimitrov; Xinhua Ji
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

3.  After microbicide failures, hope that antiviral approach will gel.

Authors:  T V Padma
Journal:  Nat Med       Date:  2008-04       Impact factor: 53.440

4.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

5.  Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.

Authors:  Antu K Dey; Carla Griffiths; Susan M Lea; William James
Journal:  RNA       Date:  2005-06       Impact factor: 4.942

6.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  Antisense oligonucleotides made of 2'-O-alkylRNA: their properties and applications in RNA biochemistry.

Authors:  A I Lamond; B S Sproat
Journal:  FEBS Lett       Date:  1993-06-28       Impact factor: 4.124

8.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers.

Authors:  Makobetsa Khati; Michael Schüman; Jamal Ibrahim; Quentin Sattentau; Siamon Gordon; William James
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  24 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 2.  Aptamers: multifunctional molecules for biomedical research.

Authors:  Jayeeta Banerjee; Marit Nilsen-Hamilton
Journal:  J Mol Med (Berl)       Date:  2013-09-18       Impact factor: 4.599

Review 3.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

4.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 5.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

6.  The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants.

Authors:  Wai Kan Chiu; Rhonda M Brand; Danielle Camp; Stacey Edick; Carol Mitchell; Sherri Karas; Amanda Zehmisch; Ken Ho; Randall E Brand; Janet Harrison; Steven Abo; Ross D Cranston; Ian McGowan
Journal:  AIDS Res Hum Retroviruses       Date:  2017-03-15       Impact factor: 2.205

7.  Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.

Authors:  Jiehua Zhou; Yi Shu; Peixuan Guo; David D Smith; John J Rossi
Journal:  Methods       Date:  2011-01-20       Impact factor: 3.608

Review 8.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807

9.  Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

Authors:  Walter Rangel Lopes de Campos; Dayaneethie Coopusamy; Lynn Morris; Bongani M Mayosi; Makobetsa Khati
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

10.  Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.

Authors:  Michael D Moore; Jonathan Cookson; Veronica K Coventry; Brian Sproat; Lorna Rabe; Ross D Cranston; Ian McGowan; William James
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.